Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
93 hedge funds and large institutions have $443M invested in Avadel Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 18 reducing their positions, and 9 closing their positions.
264% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $4.8M
250% more funds holding in top 10
Funds holding in top 10: 2 → 7 (+5)
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
100% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 18
85% more capital invested
Capital invested by funds: $239M → $443M (+$203M)
24.24% more ownership
Funds ownership: 54.15% → 78.39% (+24%)
12% more funds holding
Funds holding: 83 → 93 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$46.2M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$14.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$10.4M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$8.28M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$6.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.63M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$1.86M |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$1.73M |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$1.23M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$887K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Rockefeller Capital Management
New York
| – | -$26K | -3,794 | Closed |
|
|
USCWA
102
U.S. Capital Wealth Advisors
Austin,
Texas
| – | -$3.22K | -450 | Closed |
|
AVDL Hedge Fund Activity: Q1 2023 in Review
93 of the 6,278 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2023, worth a combined $443M — up 85% from $239M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AVDL positions and 9 closed out — a net gain of 10 holders — while 36 added to existing stakes and 18 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $46.2M. The largest seller was Millennium Management, cutting an estimated $2.63M.
- 93 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2023, up from 83 in Q4 2022.
- Funds reported $443M of Avadel Pharmaceuticals stock for Q1 2023, up 85% quarter-over-quarter.
- 19 funds opened new Avadel Pharmaceuticals positions in Q1 2023 and 9 closed out, a net change of +10 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2023 was Janus Henderson Group, an estimated $46.2M added.
- The largest Avadel Pharmaceuticals seller in Q1 2023 was Millennium Management, an estimated $2.63M sold.
Based on aggregated 13F filings for Q1 2023.